Gilead to add lipid kinase inhibitors to pipeline via Carna deal

Gilead has partnered with Carna to develop small molecule inhibitors of lipid kinases in the bellwether’s second deal to bolster its cancer portfolio since CEO Daniel O’Day arrived.